Verastem’s VS-7375 oral therapy on FDA fast track for pancreatic cancer
The experimental oral medication VS-7375 has been granted fast track designation for advanced pancreatic cancer in the U.S. The Food and Drug Administration (FDA)…
The experimental oral medication VS-7375 has been granted fast track designation for advanced pancreatic cancer in the U.S. The Food and Drug Administration (FDA)…
A study found that analyzing levels of immune cells and related molecules in the bloodstream of people with glioma can accurately distinguish between different…
The number of uterine cancer cases and related deaths — the disease’s incidence and mortality rates — in the U.S. are expected to substantially rise…
Ichnos Glenmark Innovation (IGI) is partnering with Abbvie to advance the development of ISB 2001, a multiple myeloma treatment candidate that’s now in…
ICT01, an immune-modulating therapy being developed by Imcheck Therapeutics for acute myeloid leukemia (AML), has been granted orphan drug status by the U.S. Food…
Quemliclustat has been granted an orphan drug designation in the U.S. as a potential treatment for pancreatic cancer. The U.S. Food and Drug Administration…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-101, a CAR T-cell therapy being developed by Mustang Bio to…
Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant, to be used in combination with the standard chemotherapy agent…
The U.S. Food and Drug Administration (FDA) has approved label updates for two Bristol Myers Squibb (BMS) CAR T-cell therapies, both for the treatment…
The U.S. Food and Drug Administration (FDA) has agreed to review an application for oral Inqovi (decitabine and cedazuridine) in combination with oral venetoclax for…